MYOCURE partners at the 19th Annual Meeting of the American Society of Gene & Cell Therapy
The American Society of Gene & Cell Therapy (ASGCT) hosted their annual meeting from May 4-7, 2016 in Washington, DC. For four full days, the meeting featured ground breaking clinical trial results, cutting edge technology advancements as well as social networking events. With over 1,900 participants from the world’s top gene and cell therapy professionals, it is an ideal opportunity to advance knowledge and create awareness for recent discoveries and clinical applications of gene and cell therapies.
Several MYOCURE partners were among the attendees and invited speakers. Within the scientific symposium “Frontiers in Cardiovascular Gene and Cell Therapy”, MYOCURE project coordinator Prof. Marinee Chuah gave a talk on “Next Generation Cardiac and Skeletal Muscle-Directed Gene Therapy Using Tissue Specific Transcriptional Modules Identified by Genome-Wide Computational Analysis”. In her presentation, Prof. Chuah underlined the urgent need to develop next-generation vectors for gene therapy of muscle disorders and introduced a novel transdisciplinary approach which shows great promises for safer and effective muscle-directed gene therapy.
The ASGCT is the leading professional membership organization for gene and cell therapy. The Society's members are scientists, physicians, patient advocates, and other professionals working in a wide range of settings including universities, hospitals, government agencies, foundations, biotechnology and pharmaceutical companies.
Next year’s annual meeting will take place from May 10-13, 2017 in Washington, DC. Updates on registration and attendees will be published on the ASGCT website.